ArticleImmunologic research2026
Expression of TAM receptors and their ligands in unexplained recurrent pregnancy loss.
Article in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent pregnancy loss (RPL) is clinically defined as two or more pregnancy failures before 20-24 weeks of gestation. Over 50% of RPL cases have no identified etiology and are classified as unexplained recurrent pregnancy loss (URPL). The TAM receptor tyrosine kinase (RTK) family, including TYRO3, AXL, MERTK, GAS6, and PROS1, plays critical roles in suppressing excessive inflammation and apoptosis. Although increased serum levels of these molecules have been observed in pregnancy complications such as preeclampsia, their role in URPL remains unexplored. We hypothesized that TAM receptors contribute to the immunoregulation of the maternal-fetal interface, playing a pivotal role in the development of semi-allogeneic fetuses and the pathogenesis of URPL. To test this hypothesis, we analyzed three groups: Control Endometrium (CE; n = 6), Terminated Pregnancy (TP; n = 6), and URPL (n = 6). AXL, MERTK, GAS6, and PROS1 mRNA levels were quantified by qPCR, and protein levels were evaluated using immunohistochemistry and immunoblotting. Our findings revealed a significant increase in AXL, MERTK, GAS6, and PROS1 expression in both maternal and fetal tissues of the URPL group compared to the CE and TP groups. These molecules exhibited intense perinuclear and cytoplasmic expression, particularly in immune cells and trophoblasts. This study demonstrates for the first time that AXL, MERTK, GAS6, and PROS1 are involved in URPL, highlighting their potential roles in fetal acceptance via decidual polyploid cells and in regulating inflammation and apoptosis during implantation.
Indexed as
Identifiers
42684543What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.